Advertisement

Psychopharmacology

, Volume 216, Issue 1, pp 85–90 | Cite as

A prospective open-label study of aripiprazole in fragile X syndrome

  • Craig A. EricksonEmail author
  • Kimberly A. Stigler
  • Logan K. Wink
  • Jennifer E. Mullett
  • Arlene Kohn
  • David J. Posey
  • Christopher J. McDougle
Original Investigation

Abstract

Rationale

Fragile X syndrome (FXS) is the most common inherited form of developmental disability and most common single gene cause of autism. Persons with FXS frequently exhibit irritable behavior marked by aggression, self-injury, and severe tantrums. Despite frequent clinical use of atypical antipsychotic drugs to target this behavioral cluster, no systematic trials to date have assessed the efficacy and safety of these drugs in persons with FXS.

Methods

We conducted a prospective open-label 12-week trial of aripiprazole in 12 persons aged 6–25 years (mean age, 14.3 years) with FXS who were free of concomitant psychoactive drugs.

Results

Aripiprazole use (mean dose, 9.8 mg/day) was associated with treatment response (defined by a Clinical Global Impressions-Improvement scale score of much improved or very much improved and a ≥25% improvement on the Aberrant Behavior Checklist-Irritability subscale) in 10 of 12 (87%) persons. Two individuals (13%) discontinued aripiprazole prior to study completion due to adverse events. One discontinuation was due to akathisia, mild drooling, and mild tiredness and the other due to moderate tiredness and moderate drooling. No significant changes in vital signs including weight or laboratory measures occurred during treatment with aripiprazole.

Conclusions

Aripiprazole was generally safe and well tolerated and was associated with significant improvement in irritable behavior. Given these findings, a double-blind, placebo-controlled study of aripiprazole in FXS is warranted.

Keywords

Fragile X syndrome Irritability Aripiprazole 

Notes

Acknowledgments

This work is supported by a grant from the FRAXA Research Foundation (Drs. McDougle and Erickson). The work is also supported in part by The Division of Disability and Rehabilitative Services, Indiana Family and Social Services Administration (Drs. Erickson, Wink, McDougle); National Institute of Health grant KL2 UL1 RR025761 Indiana University Clinical and Translational Sciences Institute Career Development Award (Dr. Erickson); Daniel X. and Mary Freedman Fellowship in Academic Psychiatry (Dr. Stigler); NIMH grant K23 MH082119 (Dr. Stigler); and NIMH grants R01 MH072964, R01 MH077600, R01 MH083739 (Dr. McDougle). Bristol Myers Squibb provided drug for use in this study.

References

  1. Aman MG, Singh NN, Stewart AW, Field CJ (1985) The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 5:485–491Google Scholar
  2. Amaria R, Billeisen L, Hagerman R (2001) Medication use in fragile X syndrome. Mental Health Asp Dev Dis 4:89–93Google Scholar
  3. Bailey DB Jr, Hatton DD, Tassone F, Skinner M, Taylor AK (2001) Variability in FMRP and early development in males with fragile X syndrome. Am J Ment Retard 106(1):16–27PubMedCrossRefGoogle Scholar
  4. Bailey DB Jr, Raspa M, Olmsted M, Holiday DB (2008) Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey. Am J Med Genet A 146A(16):2060–2069PubMedCrossRefGoogle Scholar
  5. Berry-Kravis E, Krause SE, Block SS, Guter S, Wuu J, Leurgans S et al (2006) Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adolesc Psychopharmacol 16(5):525–540PubMedCrossRefGoogle Scholar
  6. Berry-Kravis E, Potanos K (2004) Psychopharmacology in fragile X syndrome—present and future. Ment Retard Dev Disabil Res Rev 10(1):42–48PubMedCrossRefGoogle Scholar
  7. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T et al (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302(1):381–389PubMedCrossRefGoogle Scholar
  8. Constantino JN, Davis SA, Todd RD, Schindler MK, Gross MM, Brophy SL et al (2003) Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised. J Autism Dev Disord 33(4):427–433PubMedCrossRefGoogle Scholar
  9. Erickson CA, Stigler KA, Posey D, McDougle C (2006) Managing maladaptive behaviors in fragile X patients. Curr Psychiatry 5(10):80–92Google Scholar
  10. Erickson CA, Stigler KA, Posey DJ, McDougle CJ (2005) Risperidone in pervasive developmental disorders. Expert Rev Neurother 5(6):713–719PubMedCrossRefGoogle Scholar
  11. Erickson CA, Stigler KA, Posey DJ, McDougle CJ (2010) Aripiprazole in autism spectrum disorders and fragile X syndrome. Neurotherapeutics 7(3):258–263PubMedCrossRefGoogle Scholar
  12. Guy, W. (1976). ECDEU assessment manual for psychopharmacology, Publication No. 76-338. Washington, DC: U.S. DHEW, NIMH.Google Scholar
  13. Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A et al (2009) Advances in the treatment of fragile X syndrome. Pediatrics 123(1):378–390PubMedCrossRefGoogle Scholar
  14. Hatton DD, Hooper SR, Bailey DB, Skinner ML, Sullivan KM, Wheeler A (2002) Problem behavior in boys with fragile X syndrome. Am J Med Genet 108(2):105–116PubMedCrossRefGoogle Scholar
  15. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA (2002) The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441(3):137–140PubMedCrossRefGoogle Scholar
  16. Lord C, Pickles A, McLennan J, Rutter M, Bregman J, Folstein S et al (1997) Diagnosing autism: analyses of data from the autism diagnostic interview. J Autism Dev Disord 27(5):501–517PubMedCrossRefGoogle Scholar
  17. Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH et al (2009) A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 48(11):1110–1119PubMedCrossRefGoogle Scholar
  18. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG et al (2002) Risperidone in children with autism and serious behavioral problems. N Engl J Med 347(5):314–321PubMedCrossRefGoogle Scholar
  19. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH (1998) A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 55(7):633–641PubMedCrossRefGoogle Scholar
  20. Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD et al (2009) Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 124(6):1533–1540PubMedCrossRefGoogle Scholar
  21. Roid G, Miller L (1997) Leiter international performance scale-revised. Stoelting Company, Wood Dale (Illinois)Google Scholar
  22. Scahill L, McDougle CJ, Williams SK, Dimitropoulos A, Aman MG, McCracken JT et al (2006) Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 45(9):1114–1123PubMedCrossRefGoogle Scholar
  23. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR et al (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28(8):1400–1411PubMedCrossRefGoogle Scholar
  24. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I et al (2004) Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114(5):e634–641PubMedCrossRefGoogle Scholar
  25. Stigler KA, Diener JT, Kohn AE, Li L, Erickson CA, Posey DJ et al (2009) Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study. J Child Adolesc Psychopharmacol 19(3):265–274PubMedCrossRefGoogle Scholar
  26. Stigler KA, Posey DJ, McDougle CJ (2004) Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol 14(3):455–463PubMedCrossRefGoogle Scholar
  27. Wechsler D (1999) Wechsler Intelligence Scale for Children, 3rd edn. Psychological Corporation, San Antonio (Texas)Google Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Craig A. Erickson
    • 1
    • 2
    • 3
    Email author
  • Kimberly A. Stigler
    • 1
    • 2
    • 3
  • Logan K. Wink
    • 1
    • 2
    • 3
  • Jennifer E. Mullett
    • 1
    • 2
    • 3
  • Arlene Kohn
    • 1
    • 2
    • 3
  • David J. Posey
    • 1
    • 2
    • 3
  • Christopher J. McDougle
    • 1
    • 2
    • 3
  1. 1.Department of PsychiatryIndiana University School of MedicineIndianapolisUSA
  2. 2.Christian Sarkine Autism Treatment Center and Fragile X Research and Treatment CenterIndianapolisUSA
  3. 3.James Whitcomb Riley Hospital for ChildrenIndianapolisUSA

Personalised recommendations